Drug overdose risk with benzodiazepine treatment in young adults: Comparative analysis in privately and publicly insured individuals

Author:

Bushnell Greta A.12ORCID,Rynn Moira A.3,Gerhard Tobias14,Keyes Katherine M.5,Hasin Deborah S.56ORCID,Cerdá Magdalena7ORCID,Nyandege Abner1,Olfson Mark56

Affiliation:

1. Center for Pharmacoepidemiology and Treatment Sciences Rutgers Institute for Health, Health Care Policy and Aging Research New Brunswick NJ USA

2. Department of Biostatistics and Epidemiology Rutgers University School of Public Health Piscataway NJ USA

3. Department of Psychiatry and Behavioral Sciences Duke University School of Medicine Durham NC USA

4. Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy Rutgers University New Brunswick NJ USA

5. Department of Epidemiology Columbia University Mailman School of Public Health New York NY USA

6. Columbia University Irving Medical Center New York NY USA

7. Center for Opioid Epidemiology and Policy, Department of Population Health New York University School of Medicine New York NY USA

Abstract

AbstractBackground and AimsBenzodiazepines (BZDs) carry a risk for drug overdose and are prescribed alone or simultaneously with selective‐serotonin reuptake inhibitors (SSRIs) for the treatment of anxiety and depression in young adults. We aimed to measure risks of drug overdose following BZD treatment initiation, and simultaneous BZD and SSRI initiation, compared with SSRI treatment alone in young adults with depression or anxiety.Design, Setting, ParticipantsThe cohort study used administrative databases covering privately (MarketScan, 1/1/2009–12/31/2018) and publicly (Medicaid, 1/1/2015–12/31/2016) insured young adults (18–29 years) in the United States. Those with depression or anxiety diagnoses newly initiating BZD or SSRI treatment (without BZD or SSRI prescriptions in prior year) were included. Simultaneous “BZD + SSRI” initiation was defined as starting BZD and SSRI treatment on the same day. The cohorts included 604 664 privately insured young adults (BZD = 22%, BZD + SSRI = 10%, SSRI = 68%) and 110 493 publicly insured young adults (BZD = 23%, BZD + SSRI = 5%, SSRI = 72%).MeasurementsIncident medically treated drug overdose events were identified from emergency department and inpatient encounters (ICD poisoning codes) within 6 months of treatment initiation. Crude and propensity‐score adjusted cumulative incidence and hazard ratios (HR) were estimated. Sub‐analyses evaluated drug overdose intent.FindingsAdjusted HRs of drug overdose for BZD vs. SSRI treatment was 1.36 (95% confidence interval [CI]:1.23–1.51) in privately and 1.59 (95%CI:1.37–1.83) in publicly insured young adults. The adjusted HRs of drug overdose for BZD + SSRI treatment vs. SSRI treatment were 1.99 (95%CI:1.77–2.25) in privately and 1.98 (95%CI:1.47–2.68) in publicly insured young adults.ConclusionsAmong young adults in the United States, initiating benzodiazepine treatment for anxiety and depression, alone or simultaneously with selective‐serotonin reuptake inhibitors (SSRI), appears to have an increased risk of medically treated drug overdose compared with SSRI treatment alone. These associations were observed in publicly and privately insured individuals.

Funder

National Institute on Drug Abuse

Publisher

Wiley

Subject

Psychiatry and Mental health,Medicine (miscellaneous)

Reference49 articles.

1. Deaths: Final Data for 2019

2. Centers for Disease Control and Prevention National Center for Injury Prevention and Control.WISQARS—web‐based injury statistics query and reporting system. Available from:https://www.cdc.gov/injury/wisqars/index.html

3. CDC National Center for Health Statistics.Wide‐ranging online data for epidemiologic research (WONDER). Atlanta GA. Available from:http://wonder.cdc.gov

4. U.S. Food and Drug Administration.FDA requiring Boxed Warning updated to improve safe use of benzodiazepine drug class.2020. Available from:https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3